New NHS bladder cancer treatment doubles survival time

NHS rolls out bladder cancer treatment that can double life expectancy

It is estimated that 1,250 people a year could benefit from the new drug

New treatment for bladder cancer approved for use by the NHS

NHS approves new enfortumab vedotin and pembrolizumab combo for advanced bladder cancer, doubling survival rates and offering hope to UK patients.

New NHS bladder cancer treatment doubles survival time

Around 18,000 people in England are diagnosed with bladder cancer each year, and experts hope the new treatment - a combination of two drugs - will help patients spend far more time with their loved ones.

Breakthrough NHS bladder cancer treatment doubles survival rate

More than 1,000 patients will receive the treatment annually — which was found to extend lives, halt progression and even lead to cancer-free prognoses

First new treatment for advanced bladder cancer in decades given green light

Experts said the approval of the new treatment combination would bring a ‘fundamental shift’ in care for patients with late-stage disease.

New advanced bladder cancer treatment can ‘double chances of survival’

Treatment for advanced bladder cancer had not significantly changed for 40 years. Now thousands are set to benefit